JCR Pharmaceuticals Co., Ltd. (4552) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for JCR Pharmaceuticals Co., Ltd. (4552:JPX), powered by AI.

Current Price
¥466
P/E Ratio
-12.1
Market Cap
57.7B
Sector
Healthcare
What is the JCR Pharmaceuticals Co., Ltd. stock price forecast?

JCR Pharmaceuticals Co., Ltd. is currently trading at ¥466. View real-time AI analysis on Alpha Lenz.

What is JCR Pharmaceuticals Co., Ltd. insider trading activity?

View the latest insider trading data for JCR Pharmaceuticals Co., Ltd. on Alpha Lenz.

What is JCR Pharmaceuticals Co., Ltd.'s P/E ratio?

JCR Pharmaceuticals Co., Ltd.'s P/E ratio is -12.1.

JCR Pharmaceuticals Co., Ltd.

JPX · 4552
¥466+18(+4.02%)Market closedJPX regular session 09:00–15:00 JST
Ask about JCR Pharmaceuticals Co., Ltd.'s future dividend policy...
Alpha Chat Insight

JCR Pharmaceuticals Co., Ltd. trades at a P/E of -12.1 (undervalued) with modest ROE of -9.2%.

Ask for details

Company Overview

JCR Pharmaceuticals Co., Ltd. is a prominent biotechnology company engaged in the development, manufacture, and distribution of pharmaceutical products. The company focuses primarily on innovative treatments for rare diseases and biopharmaceuticals, utilizing advanced recombinant DNA and protein engineering technologies. JCR Pharmaceuticals is recognized for its contributions to enzyme replacement therapies and regenerative medicines, which address unmet medical needs in diverse therapeutic areas such as lysosomal storage disorders. Incorporated in Japan, JCR Pharmaceuticals plays a significant role in the pharmaceutical industry by investing heavily in research and development to bring cutting-edge therapies to the global market. The company's dedication to innovation has established it as a key player in the biopharmaceutical segment, where it actively collaborates with academic institutions and industry partners to enhance its product pipeline. With its strong emphasis on improving patient outcomes through advanced biologics, JCR Pharmaceuticals continues to bolster its market position, impacting sectors such as healthcare and life sciences with its specialized offerings.

CEOMr. Shin Ashida
SectorHealthcare
IndustryDrug Manufacturers - General
Employees987

Company Statistics

FY 2025

Profile

¥57,707,363,970Market Cap
¥33,072,000,000Revenue
0.00Shares Out
987Employees

Margins

65.73%Gross
-11.36%EBITDA
-20.11%Operating
-19.39%Pre-Tax
-14.20%Net

Valuation

-12.13P/E
1.23P/B
1.74EV/Sales
-22.10EV/EBITDA
-3.75P/FCF

Growth (CAGR)

-13.49%Rev 3Yr
5.94%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-4.53%ROA
-9.22%ROE
-6.04%ROIC

Financial Health

¥13,196,000,000Cash & Cash Equivalents
¥44,224,000,000Net Debt
121.05%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

JCR Pharmaceuticals Co., Ltd. (ticker: 4552) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - General). It has approximately 987 employees. Market cap is $57.7B.

The current price is 466 with a P/E ratio of -12.13x and P/B of 1.23x.

ROE is -9.22% and operating margin is -20.11%. Annual revenue is $33.1B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
JCR Pharmaceuticals Co., Ltd. (4552) Stock Forecast 2026 ¥466 — Price, Financials & Analyst Targets | Alpha Lenz